PA8790101A1 - Derivados de aminoalquilazol como antagonistas de histamina-3 - Google Patents

Derivados de aminoalquilazol como antagonistas de histamina-3

Info

Publication number
PA8790101A1
PA8790101A1 PA20088790101A PA8790101A PA8790101A1 PA 8790101 A1 PA8790101 A1 PA 8790101A1 PA 20088790101 A PA20088790101 A PA 20088790101A PA 8790101 A PA8790101 A PA 8790101A PA 8790101 A1 PA8790101 A1 PA 8790101A1
Authority
PA
Panama
Prior art keywords
histamine
aminoalquilazol
antagonists
derivatives
affected
Prior art date
Application number
PA20088790101A
Other languages
English (en)
Inventor
Jonathan Laird Gross
Albert Jean Robichaud
Alessandro Mazzacani
Marla Jean Williams
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8790101A1 publication Critical patent/PA8790101A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA 1:Y EL USO DE ESTE PARA EL TRATAMIENTO DE UN TRASTORNO DEL SISTEMA NERVIOSO CENTRAL RELACIONADO CON O AFECTADO POR EL RECEPTOR DE HISTAMINA-3.
PA20088790101A 2007-07-16 2008-07-16 Derivados de aminoalquilazol como antagonistas de histamina-3 PA8790101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95974107P 2007-07-16 2007-07-16

Publications (1)

Publication Number Publication Date
PA8790101A1 true PA8790101A1 (es) 2009-02-09

Family

ID=39708793

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088790101A PA8790101A1 (es) 2007-07-16 2008-07-16 Derivados de aminoalquilazol como antagonistas de histamina-3

Country Status (10)

Country Link
US (1) US7803825B2 (es)
EP (1) EP2170875A1 (es)
JP (1) JP2010533725A (es)
AR (1) AR067549A1 (es)
CA (1) CA2693138A1 (es)
CL (1) CL2008002088A1 (es)
PA (1) PA8790101A1 (es)
PE (1) PE20090812A1 (es)
TW (1) TW200920356A (es)
WO (1) WO2009012252A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009029A2 (en) * 2008-07-15 2010-01-21 Wyeth Methods for the preparation of azole compounds
EP2445899B1 (en) * 2009-06-26 2016-05-11 Sanofi Novel fumarate salts of a histamine h3 receptor antagonist
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
JP2013508461A (ja) * 2009-10-27 2013-03-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN103570705B (zh) * 2012-07-18 2017-01-25 中国医学科学院医药生物技术研究所 取代的n‑((1',3'‑杂唑‑4'‑基)‑甲基)‑4‑苯甲酰基六氢吡啶类化合物及其用途
ES2775782T3 (es) 2016-03-15 2020-07-28 Bayer Cropscience Ag Sulfonilamidas sustituidas para combatir parásitos animales
WO2023140709A1 (ko) * 2022-01-21 2023-07-27 재단법인 한국파스퇴르연구소 항박테리아 활성 옥사졸 유도체 화합물 및 이의 의약 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4168853A (en) * 1977-06-08 1979-09-25 Vetco, Inc. Shiftable ring gasket retainer for flanged connectors
US4166853A (en) 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
AU674207B2 (en) 1993-04-07 1996-12-12 Otsuka Pharmaceutical Co., Ltd. N-acylated 4-amino piperidine derivatives
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ES2210747T3 (es) * 1997-05-01 2004-07-01 Eli Lilly And Company Agentes antitromboticos.
WO2001042224A1 (en) 1999-12-09 2001-06-14 Mitsubishi Pharma Corporation Carboxyamido derivatives
WO2001074773A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Phenyl-substituted indoles as histamine h3-receptor antagonists
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
DE60329910D1 (de) 2002-03-29 2009-12-17 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
EP1603917B1 (en) 2003-03-14 2010-11-24 MediGene Ltd. Immunomodulating heterocyclic compounds
MY139355A (en) * 2004-05-14 2009-09-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
DK1786790T3 (da) * 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
US7705025B2 (en) 2004-08-23 2010-04-27 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
UY29149A1 (es) 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
WO2006078775A1 (en) * 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
CA2645731A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
AR059961A1 (es) 2006-03-20 2008-05-14 Glaxo Group Ltd Compuesto derivado de fenil tetrahidro-indazol, composiciones farmaceuticas que lo comprenden, usos para preparar un medicamento para el tratamiento de una enfermedad mediada por una reduccion o desequilibrio en la funcion del receptor de glutamato y procesos para su preparacion
US20070238718A1 (en) 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Also Published As

Publication number Publication date
JP2010533725A (ja) 2010-10-28
CL2008002088A1 (es) 2008-09-05
WO2009012252A1 (en) 2009-01-22
EP2170875A1 (en) 2010-04-07
US7803825B2 (en) 2010-09-28
CA2693138A1 (en) 2009-01-22
PE20090812A1 (es) 2009-06-14
US20090023707A1 (en) 2009-01-22
TW200920356A (en) 2009-05-16
AR067549A1 (es) 2009-10-14

Similar Documents

Publication Publication Date Title
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ECSP099553A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
CR20140085A (es) Inhibidores de pde10 de pirimidina
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
UY31931A (es) Compuestos de diarilo y uso de los mismos